News
Resources
Blog
Sites
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
By Megan Van Etten | August 5, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
By Mike Ybarra | August 4, 2021
Bolstered by incredible progress in the fight against COVID-19, the biopharmaceutical industry continues to work around the clock to research, develop and manufacture vaccines and therapeutics to...
Read More
ICYMI: Event spotlights how we can make Medicare work better for patients
By Katie Koziara | August 4, 2021
Last month, PhRMA sponsored “Making Medicare Work Better for Patients,” an event hosted by The Hill. During the event, policymakers, patient advocates and biopharmaceutical leaders spoke about how...
Read More
The future of the rebate rule: Will policymakers stand with patients?
By Stephen J. Ubl | August 2, 2021
Policymakers will soon decide whether to stand by new Medicare changes that will help lower costs for beneficiaries at the pharmacy counter or abandon these changes to fund government programs...
Read More
Celebrating Medicare’s 56th anniversary
By Gabby Migliara | July 30, 2021
For 56 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. Today marks Medicare’s anniversary and to...
Read More
Increasing global access to vaccines by optimizing production
By Megan Van Etten | July 29, 2021
The following is part of a series of posts detailing each of the five strategies to advance global COVID-19 vaccine equity – which rely on and benefit from a strong intellectual property ecosystem.
Read More
Recognizing Hepatitis R&D on World Hepatitis Day
By Andrew Powaleny | July 28, 2021
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease...
Read More
340B hospitals among those that provide lowest levels of community benefit across the country
By Nicole Longo | July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....
Read More
We Work for Health: Discovering champions, even amid challenging times
By Ryan Garofalo | July 26, 2021
For over a decade, We Work For Health has sought to highlight the incredible men and women who create hope for patients, serve as changemakers and ensure the continued vibrancy of our economy. We...
Read More
Government “negotiation” could have devastating consequences for Medicare enrollees
By Gabby Migliara | July 23, 2021
Some members of Congress are considering significant changes to Medicare that could have a devastating effect on millions of Americans. Proponents call these changes government “negotiation,” but...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
